AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NewAmsterdam Pharma Co N.V.'s Chief Accounting Officer Sells 8,269 Shares
ByAinvest
Wednesday, Aug 27, 2025 5:14 pm ET1min read
NewAmsterdam Pharma Co N.V.[NAMS] has announced that Chief Accounting Officer Kooij Louise Frederika has executed a sale of 8269 shares at a price per share of $24.86 on August 25, 2025.
NewAmsterdam Pharma Co N.V. [NAMS] has announced that Chief Accounting Officer Kooij Louise Frederika has executed a sale of 8,269 shares at a price per share of $24.86 on August 25, 2025. This transaction follows a series of positive developments for the company, including recent analyst upgrades and a strategic partnership with Piramal Pharma Solutions.The sale of shares by the CFO, a key executive in the company, may be seen as a sign of confidence in the company's prospects or a strategic move to diversify personal holdings. However, the exact reasons for the sale are not specified in the announcement.
Investors have been closely following NewAmsterdam Pharma's progress, particularly in relation to its CETP inhibitor, obicetrapib. Wells Fargo initiated coverage on the stock with an Overweight rating and a $45.00 price target, citing the drug's potential to reduce major adverse cardiovascular events (MACE) and its strong clinical trial results [1]. Additionally, the company has been making significant strides in its commercialization efforts, including a recent investment in a dedicated oral solid dosage (OSD) suite at Piramal Pharma Solutions' Sellersville facility [2].
Despite these positive developments, NewAmsterdam Pharma faces challenges, including the extended timeline for key trial results expected in late 2026. Goldman Sachs initiated coverage with a Neutral rating and a $27.00 price target, citing this extended timeline [1]. The company's ability to navigate these challenges and deliver on its clinical and commercial promises will be key to maintaining investor confidence.
References:
[1] https://www.investing.com/news/analyst-ratings/newamsterdam-pharma-stock-initiated-at-overweight-by-wells-fargo-93CH-4208426
[2] https://www.nasdaq.com/press-release/piramal-pharma-solutions-and-newamsterdam-pharma-invest-dedicated-suite-enhance-oral
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet